Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays.

10520 Background: The ALK inhibitor crizotinib offers a new standard of care for patients with EML4-ALK fusion oncogene-positive advanced NSCLC. Two top priorities for its widespread clinical use a...